Fungi · Scientific monograph
Grifola frondosa
Maitake / Hen-of-the-Woods
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Immunological Research, Glucose & Metabolic Research, Cellular & Immune Studies
Research overview
Historical use
Used in Traditional Chinese and Japanese medicine as a tonic and food. Known in Japan as 'Maitake' (dancing mushroom), legend holds that people danced with joy upon finding it in the wild. Used historically for fatigue, diabetes-like symptoms, and immune support. Cultivated commercially since the 1970s in Japan.
Modern research context
D-fraction and MD-fraction (beta-1,6/1,3-glucan protein complexes) have shown immunomodulatory and anti-tumour effects in preclinical studies and small human trials; a meta-analysis confirmed polysaccharide anti-tumour activity [1]. Neurotrophic properties, including support of nerve growth factor (NGF) signalling, are under investigation [2]. Anti-proliferative activity in keratinocyte-related pathways via MAPK inhibition has been documented [3]. Maitake is included in reviews of edible mushroom anti-cancer potential across multiple cancer types [4]. Neuroprotective bioactivities are an emerging research focus [5].
Adverse effects
Generally well tolerated. Mild GI symptoms. Risk of hypoglycaemia with antidiabetic medications. Theoretical bleeding risk.
Contraindications
Antidiabetic medications — risk of additive hypoglycaemia. Anticoagulants — theoretical risk. Immunosuppressants — pharmacodynamic antagonism.
Clinical and phytochemical data
Used part
Fruiting body
Primary active compounds
D-fraction / MD-fraction (beta-1,6/1,3-glucan-protein complex)
SX-fraction (alpha-glucan)
Polysaccharides
Ergosterol
Phospholipids
Mechanism of action
D-fraction binds Dectin-1 and TLR-2 on macrophages and dendritic cells, activating innate and adaptive immune responses; increases NK cell and CD4+ T-cell activity. Anti-tumour mechanism involves upregulation of TNF-α, IL-12, and direct tumour cytotoxicity. SX-fraction increases insulin receptor sensitivity via PPAR-γ activation, reducing blood glucose and insulin resistance.
Pharmacokinetics
Absorption
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Beta-glucan fractions have limited oral bioavailability; partially absorbed in low-molecular-weight fractions and active at gut mucosal level. SX-fraction absorption profile not fully characterised.
Distribution
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — D-fraction distributes to GALT, spleen, and lymph nodes in animal models; higher affinity for lymphoid tissue and tumour microenvironment. SX-fraction distribution to peripheral tissues (muscle, liver, adipose) demonstrated in rodent models. Human tissue distribution data are not available.
Metabolism
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Intestinal microbial fermentation of polysaccharides produces short-chain fatty acids (SCFAs). Absorbed fractions undergo hepatic metabolism.
Excretion
No human pharmacokinetic data are available for this species. The following is derived from preclinical animal studies and in vitro data only, and may not reflect human pharmacology. — Primarily fecal; smaller metabolites via renal route.
Safety and interactions
Drug interactions
Lack of clinical studies prevents interaction grading. Unknown safety profile with concomitant drug use.
Toxicity
LD50 >3 g/kg (oral, rodents). No organ toxicity in chronic animal studies. Human trials up to 6 g/day showed no serious adverse events.
Special precautions
Pregnancy
Insufficient clinical data. Avoid concentrated extracts during pregnancy.
Lactation
No data on breast milk excretion. Dietary amounts likely safe; supplemental doses — insufficient data.
Hepatic impairment
No hepatotoxicity documented. Standard monitoring recommended.
Renal impairment
No specific risk identified. No dose adjustment data available.
Sources and references
- [1] - Zhao F., "Antitumor activities of Grifola frondosa (Maitake) polysaccharide: A meta-analysis based on preclinical evidence.", J Ethnopharmacol, 2021, PMID: 34271115
- [2] - Naguib AM., "Maitake Medicinal Mushroom, Grifola frondosa (Agaricomycetes), and Its Neurotrophic Properties.", Int J Med Mushrooms, 2023, PMID: 36749053
- [3] - Choi EJ., "Extracts of Grifola frondosa inhibit the MAPK signaling pathways involved in keratinocyte hyperproliferation.", Nutr Res Pract, 2023, PMID: 38053833
- [4] - Gariboldi MB., "Anti-Cancer Potential of Edible/Medicinal Mushrooms in Breast Cancer.", Int J Mol Sci, 2023, PMID: 37373268
- [5] - Abdelmoaty MM., "Neuroprotective Mushrooms.", NeuroImmune Pharm Ther, 2024, PMID: 40370689